{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T07:30:06Z","timestamp":1769931006410,"version":"3.49.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hepatosplenic T cell lymphoma (HSTCL) is a particularly difficult-to-treat form of lymphoma, with many patients exhibiting primary resistance to chemotherapy. At present, no effective strategy for treating relapsed and refractory HSTCL has been established, with treatment being hampered by questions of how best to overcome chemoresistance to allow patients to attain more durable therapeutic benefits. While there have been marked advances in immunotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the primary approaches to curing HSTCL. Of patients who undergo immunochemotherapeutic treatment, many are resistant to conventional chemotherapeutic drugs yet remain sensitive to radiotherapy. We selected to employ a transplant pretreatment regimen consisting of total -body irradiation (TBI) and administered this regimen to two patients with HSTCL. Both patients achieved complete remission (CR) after transplantation, demonstrating extended periods without disease recurrence. We systematic reviewed previously published instances involving allo-HSCT in patients with HSTCL. We have found a total of 67 patients who have received allo-HSCT. In general, age&amp;lt;45 and the status of CR at HSCT may have a more favorable prognosis. Although the impact of TBI on prognosis was not found to be substantial, patients in the TBI group had higher 3-year overall survival (66.7% vs. 71.1%) and 5-year overall survival (58.4% vs. 71.1%) compared to patients in the non-TBI group. In addition, the relapse rate of the TBI group is approximately half that of the non-TBI group. This regimen is well tolerated and associated with low recurrence rates or complications, suggesting that it represents a viable pretreatment regimen for young HSTCL patients undergoing allogeneic HSCT.<\/jats:p>","DOI":"10.3389\/fonc.2024.1345464","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T04:41:08Z","timestamp":1706503268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Allo-HSCT with TBI-based preconditioning for hepatosplenic T-cell lymphoma: two case reports and systematic review of literature"],"prefix":"10.3389","volume":"14","author":[{"given":"Can","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiwen","family":"Miu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenxian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V75.11.2213.2213","article-title":"Hepatosplenic T-cell lymphoma: sinusal\/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta","volume":"75","author":"Farcet","year":"1990","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V88.11.4265.bloodjournal88114265","article-title":"Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2014.09.001","article-title":"Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha\/beta (\u03b1\u03b2) T-cell lymphoma","volume":"3","author":"Catania","year":"2014","journal-title":"Leuk Res Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12288-010-0051-1","article-title":"Hepatosplenic T-cell lymphoma","volume":"27","author":"Alsohaibani","year":"2011","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1309\/BM40-YM6J-9T3X-MH8H","article-title":"Hepatosplenic gamma\/delta T-cell lymphoma in bone marrow: a sinusoidal neoplasm with blastic cytologic features","volume":"116","author":"Vega","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clml.2012.09.002","article-title":"Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: A single institution experience","volume":"13","author":"Voss","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13213","article-title":"Hepatosplenic \u03b3\u03b4 T-cell lymphoma of two adolescents: Case report and retrospective literature review in children, adolescents, and young adults","volume":"22","author":"McThenia","year":"2018","journal-title":"Pediatr Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00594","article-title":"Hepatosplenic \u03b3-\u03b4 T-cell lymphoma: who is on your speed dial","volume":"15","author":"Krishnan","year":"2019","journal-title":"J Oncol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.169","article-title":"Gamma-delta T-cell lymphomas","volume":"6","author":"Tripodo","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B10","volume-title":"WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2008"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.021","article-title":"Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review","volume":"10","author":"Ochenrider","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1675","article-title":"Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients","volume":"102","author":"Belhadj","year":"2003","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn751","article-title":"Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment","volume":"20","author":"Falchook","year":"2009","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.280","article-title":"Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party","volume":"29","author":"Tanase","year":"2015","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in the current era: a study in acute myeloid leukemia patients [published correction appears in Bone Marrow Transplant]","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2020.09.013","article-title":"Outcomes of hepatosplenic T-cell lymphoma: the mayo clinic experience","volume":"21","author":"Bojanini","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1345464\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T04:41:11Z","timestamp":1706503271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1345464\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":19,"alternative-id":["10.3389\/fonc.2024.1345464"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1345464","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"article-number":"1345464"}}